Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL

Watchlist Manager
Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Watchlist
Price: 3.945 USD 0.64%
Market Cap: 280.5m USD
Have any thoughts about
Zentalis Pharmaceuticals Inc?
Write Note

Intrinsic Value

ZNTL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ZNTL stock under the Base Case scenario is 3.025 USD. Compared to the current market price of 3.945 USD, Zentalis Pharmaceuticals Inc is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ZNTL Intrinsic Value
3.025 USD
Overvaluation 23%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Zentalis Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ZNTL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ZNTL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Zentalis Pharmaceuticals Inc

Provide an overview of the primary business activities
of Zentalis Pharmaceuticals Inc.

What unique competitive advantages
does Zentalis Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Zentalis Pharmaceuticals Inc face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Zentalis Pharmaceuticals Inc.

Provide P/S
for Zentalis Pharmaceuticals Inc.

Provide P/E
for Zentalis Pharmaceuticals Inc.

Provide P/OCF
for Zentalis Pharmaceuticals Inc.

Provide P/FCFE
for Zentalis Pharmaceuticals Inc.

Provide P/B
for Zentalis Pharmaceuticals Inc.

Provide EV/S
for Zentalis Pharmaceuticals Inc.

Provide EV/GP
for Zentalis Pharmaceuticals Inc.

Provide EV/EBITDA
for Zentalis Pharmaceuticals Inc.

Provide EV/EBIT
for Zentalis Pharmaceuticals Inc.

Provide EV/OCF
for Zentalis Pharmaceuticals Inc.

Provide EV/FCFF
for Zentalis Pharmaceuticals Inc.

Provide EV/IC
for Zentalis Pharmaceuticals Inc.

Show me price targets
for Zentalis Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Zentalis Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Zentalis Pharmaceuticals Inc?

What are the Net Income projections
for Zentalis Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Zentalis Pharmaceuticals Inc?

What are the EPS projections
for Zentalis Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Zentalis Pharmaceuticals Inc?

What are the EBIT projections
for Zentalis Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Zentalis Pharmaceuticals Inc?

Compare the revenue forecasts
for Zentalis Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Zentalis Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Zentalis Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Zentalis Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Zentalis Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Zentalis Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Zentalis Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Zentalis Pharmaceuticals Inc.

Provide ROE
for Zentalis Pharmaceuticals Inc.

Provide ROA
for Zentalis Pharmaceuticals Inc.

Provide ROIC
for Zentalis Pharmaceuticals Inc.

Provide ROCE
for Zentalis Pharmaceuticals Inc.

Provide Gross Margin
for Zentalis Pharmaceuticals Inc.

Provide Operating Margin
for Zentalis Pharmaceuticals Inc.

Provide Net Margin
for Zentalis Pharmaceuticals Inc.

Provide FCF Margin
for Zentalis Pharmaceuticals Inc.

Show all solvency ratios
for Zentalis Pharmaceuticals Inc.

Provide D/E Ratio
for Zentalis Pharmaceuticals Inc.

Provide D/A Ratio
for Zentalis Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Zentalis Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Zentalis Pharmaceuticals Inc.

Provide Quick Ratio
for Zentalis Pharmaceuticals Inc.

Provide Current Ratio
for Zentalis Pharmaceuticals Inc.

Provide Cash Ratio
for Zentalis Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Zentalis Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Zentalis Pharmaceuticals Inc?

What is the current Free Cash Flow
of Zentalis Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Zentalis Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc

Current Assets 439.6m
Cash & Short-Term Investments 426.4m
Receivables 3.3m
Other Current Assets 10m
Non-Current Assets 52.1m
PP&E 38.8m
Intangibles 3.7m
Other Non-Current Assets 9.5m
Current Liabilities 66.7m
Accounts Payable 20.4m
Accrued Liabilities 45.8m
Other Current Liabilities 425k
Non-Current Liabilities 42.4m
Other Non-Current Liabilities 42.4m
Efficiency

Earnings Waterfall
Zentalis Pharmaceuticals Inc

Revenue
40.6m USD
Operating Expenses
-261.1m USD
Operating Income
-220.6m USD
Other Expenses
25.9m USD
Net Income
-194.7m USD

Free Cash Flow Analysis
Zentalis Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ZNTL Profitability Score
Profitability Due Diligence

Zentalis Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

21/100
Profitability
Score

Zentalis Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

ZNTL Solvency Score
Solvency Due Diligence

Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Zentalis Pharmaceuticals Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ZNTL Price Targets Summary
Zentalis Pharmaceuticals Inc

Wall Street analysts forecast ZNTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZNTL is 10.098 USD with a low forecast of 4.04 USD and a high forecast of 21 USD.

Lowest
Price Target
4.04 USD
2% Upside
Average
Price Target
10.098 USD
156% Upside
Highest
Price Target
21 USD
432% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ZNTL?

Click here to dive deeper.

Dividends

Zentalis Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ZNTL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Zentalis Pharmaceuticals Inc Logo
Zentalis Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

278.7m USD

Dividend Yield

0%

Description

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

Contact

NEW YORK
New York City
1359 Broadway, Suite 1710, Suite 2201
+12124333791.0
www.zentalis.com

IPO

2020-04-03

Employees

177

Officers

CEO & Director
Dr. Kimberly Lynn Blackwell M.D.
Co-Founder, President, Interim CFO, Interim Treasurer & Director
Mr. Cameron S. Gallagher M.B.A.
Chief Legal Officer & Corporate Secretary
Ms. Andrea Paul J.D.
VP of Finance & Interim Principal Accounting Officer
Mr. Vincent Vultaggio
Chief Scientific Officer
Dr. Mark Lackner Ph.D.
Chief Strategy Officer
Ms. Kimberly Freeman
Show More
Chief Business Officer
Dr. Kyle Rasbach Ph.D., Pharm.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one ZNTL stock?

The intrinsic value of one ZNTL stock under the Base Case scenario is 3.025 USD.

Is ZNTL stock undervalued or overvalued?

Compared to the current market price of 3.945 USD, Zentalis Pharmaceuticals Inc is Overvalued by 23%.

Back to Top